{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T01:49:06Z","timestamp":1773712146155,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jgar.2024.05.017","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T02:06:16Z","timestamp":1718935576000},"page":"216-222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["In vitro activity of ceftolozane\/tazobactam against Gram-negative bacilli isolated from pediatric patients: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017\u20132021, China"],"prefix":"10.1016","volume":"38","author":[{"given":"Xinli","family":"Mu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengcheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunsong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jgar.2024.05.017_bib0001","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3390\/antibiotics10040393","article-title":"Antibiotic resistance in pediatric infections: global emerging threats, predicting the near future","volume":"10","author":"Romandini","year":"2021","journal-title":"Antibiotics (Basel)"},{"issue":"4","key":"10.1016\/j.jgar.2024.05.017_bib0002","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1128\/CMR.00040-09","article-title":"Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms","volume":"22","author":"Lister","year":"2009","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.jgar.2024.05.017_bib0003","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.jgar.2024.05.017_bib0004","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S1473-3099(19)30414-1","article-title":"Aetiology of invasive bacterial infection and antimicrobial resistance in neonates in sub-Saharan Africa: a systematic review and meta-analysis in line with the STROBE-NI reporting guidelines","volume":"19","author":"Okomo","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2024.05.017_bib0005","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.2147\/IDR.S180905","article-title":"Ceftolozane\/tazobactam for the treatment of complicated intra-abdominal and urinary tract infections: current perspectives and place in therapy","volume":"12","author":"Escol\u00e0-Verg\u00e9","year":"2019","journal-title":"Infect Drug Resist"},{"issue":"12","key":"10.1016\/j.jgar.2024.05.017_bib0006","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/AAC.01802-13","article-title":"Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012)","volume":"57","author":"Farrell","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.jgar.2024.05.017_bib0007","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jgar.2024.05.017_bib0008","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1128\/AAC.01737-10","article-title":"Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes","volume":"55","author":"Sader","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.05.017_bib0009","series-title":"Tetracyclines. In red book: 2009 report of the committee on infectious diseases","author":"Pickering","year":"2009"},{"issue":"4","key":"10.1016\/j.jgar.2024.05.017_bib0010","doi-asserted-by":"crossref","first-page":"e1034","DOI":"10.1542\/peds.2011-1496","article-title":"The use of systemic and topical fluoroquinolones","volume":"128","author":"Bradley","year":"2011","journal-title":"Pediatrics"},{"issue":"11","key":"10.1016\/j.jgar.2024.05.017_bib0011","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/INF.0000000000002170","article-title":"Pharmacokinetics and safety of single intravenous doses of ceftolozane\/tazobactam in children with proven or suspected Gram-negative infection","volume":"37","author":"Bradley","year":"2018","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.jgar.2024.05.017_bib0012","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/INF.0000000000003832","article-title":"Safety and efficacy of ceftolozane\/tazobactam versus meropenem in neonates and children with complicated urinary tract infection, including pyelonephritis: a phase 2, randomized clinical trial","volume":"42","author":"Roilides","year":"2023","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.jgar.2024.05.017_bib0013","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/antibiotics8020067","article-title":"Use of ceftolozane\/tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa pneumonia in a pediatric patient with combined immunodeficiency (CID): a case report from a tertiary hospital in Saudi Arabia","volume":"8","author":"Zikri","year":"2019","journal-title":"Antibiotics (Basel)"},{"issue":"8","key":"10.1016\/j.jgar.2024.05.017_bib0014","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/jpc.14388","article-title":"Successful ceftolozane-tazobactam rescue therapy in a child with endocarditis caused by multidrug-resistant Pseudomonas aeruginosa","volume":"55","author":"Mart\u00edn-Caza\u00f1a","year":"2019","journal-title":"J Paediatr Child Health"},{"issue":"1","key":"10.1016\/j.jgar.2024.05.017_bib0015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/jpids\/piw093","article-title":"Incidence and outcomes of infections caused by multidrug-resistant Enterobacteriaceae in children, 2007-2015","volume":"7","author":"Meropol","year":"2018","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"8","key":"10.1016\/j.jgar.2024.05.017_bib0016","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/cid\/ciz173","article-title":"A primer on AmpC \u03b2-lactamases: necessary knowledge for an increasingly multidrug-resistant world","volume":"69","author":"Tamma","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jgar.2024.05.017_bib0017","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/1120009X.2021.1888030","article-title":"Comparative in vitro effectiveness of ceftolozane\/tazobactam against pediatric gram-negative drug-resistant isolates","volume":"33","author":"Kanwar","year":"2021","journal-title":"J Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2024.05.017_bib0018","first-page":"725","article-title":"1273. Activity of ceftolozane\/tazobactam and comparators against Enterobacterales and P. aeruginosa isolates from pediatric patients\u2014SMART United States 2017-2019","volume":"8","author":"Lob","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"10.1016\/j.jgar.2024.05.017_bib0019","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/cid\/cix893","article-title":"Carbapenemase-producing organisms: a global scourge","volume":"66","author":"Bonomo","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.05.017_bib0020","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fcimb.2020.00314","article-title":"Dissemination of carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) among carbapenem-resistant Enterobacteriaceae isolated from adult and children patients in China","volume":"10","author":"Han","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"10.1016\/j.jgar.2024.05.017_bib0021","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1128\/CMR.00036-08","article-title":"AmpC beta-lactamases","volume":"22","author":"Jacoby","year":"2009","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.jgar.2024.05.017_bib0022","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40265-013-0168-2","article-title":"Ceftolozane\/tazobactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli","volume":"74","author":"Zhanel","year":"2014","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.jgar.2024.05.017_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105883","article-title":"Activity of ceftolozane-tazobactam against Gram-negative pathogens isolated from lower respiratory tract infections in the Asia-Pacific region: SMART 2015-2016","volume":"55","author":"Kuo","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.05.017_bib0024","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jgar.2021.11.011","article-title":"In vitro activity of ceftolozane\/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries\u2014SMART 2017-2019","volume":"29","author":"Lob","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2024.05.017_bib0025","first-page":"S725","article-title":"1274. Activity of ceftolozane\/tazobactam, imipenem\/relebactam, and comparators against Pseudomonas aeruginosa isolates from patients with bloodstream and other infection types\u2014SMART United States\/Canada 2018-2019","volume":"8","author":"Lob","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2024.05.017_bib0026","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1093\/ofid\/ofy343","article-title":"Geographic and temporal patterns of antimicrobial resistance in Pseudomonas aeruginosa over 20 years from the SENTRY antimicrobial surveillance program, 1997-2016","volume":"6","author":"Shortridge","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.jgar.2024.05.017_bib0027","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/jcpt.13317","article-title":"Characterization of Isavuconazole serum concentrations after enteral feeding tube administration in a hospitalized cohort: a case series","volume":"46","author":"Spivey","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jgar.2024.05.017_bib0028","series-title":"Pharmacology","author":"Yang","year":"2013"},{"issue":"5","key":"10.1016\/j.jgar.2024.05.017_bib0029","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/femsre\/fux020","article-title":"Structure, function and regulation of Pseudomonas aeruginosa porins","volume":"41","author":"Chevalier","year":"2017","journal-title":"FEMS Microbiol Rev"},{"issue":"2","key":"10.1016\/j.jgar.2024.05.017_bib0030","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jmb.2011.12.045","article-title":"Crystal structure and regulation mechanisms of the CyaB adenylyl cyclase from the human pathogen Pseudomonas aeruginosa","volume":"416","author":"Topal","year":"2012","journal-title":"J Mol Biol"},{"issue":"8","key":"10.1016\/j.jgar.2024.05.017_bib0031","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/jpids\/piad055","article-title":"Antimicrobial susceptibility among Gram-negative isolates in pediatric patients in Latin America, Africa-middle east, and Asia from 2016 to 2020 compared to 2011-2015: results from the ATLAS surveillance study","volume":"12","author":"Yang","year":"2023","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"1","key":"10.1016\/j.jgar.2024.05.017_bib0032","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pedneo.2019.05.009","article-title":"The clinical features and therapy of community-acquired gram negative bacteremia in children less than three years old","volume":"61","author":"Kuo","year":"2020","journal-title":"Pediatr Neonatol"},{"issue":"5","key":"10.1016\/j.jgar.2024.05.017_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106441","article-title":"Antimicrobial susceptibility among Gram-negative isolates in pediatric patients in Europe from 2013 to 2018 compared to 2004-2012: results from the ATLAS surveillance study","volume":"58","author":"Seifert","year":"2021","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"10.1016\/j.jgar.2024.05.017_bib0034","doi-asserted-by":"crossref","first-page":"e00875","DOI":"10.1128\/AAC.00875-17","article-title":"Multicenter evaluation of ceftazidime-avibactam and ceftolozane-tazobactam inhibitory activity against meropenem-nonsusceptible Pseudomonas aeruginosa from blood, respiratory tract, and wounds","volume":"61","author":"Grupper","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.jgar.2024.05.017_bib0035","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.jgar.2024.05.017_bib0036","first-page":"352","article-title":"Multidrug- and carbapenem-resistant Pseudomonas aeruginosa in children, United States, 1999-2012","volume":"6","author":"Logan","year":"2017","journal-title":"J Pediatric Infect Dis Soc"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524001073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524001073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T09:41:55Z","timestamp":1726393315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716524001073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":36,"alternative-id":["S2213716524001073"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2024.05.017","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of ceftolozane\/tazobactam against Gram-negative bacilli isolated from pediatric patients: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017\u20132021, China","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2024.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. and The Author(s). Published by Elsevier Ltd on behalf of International Society for Chemotherapy of Infection and Cancer.","name":"copyright","label":"Copyright"}]}}